Dr Frank Hensel holds a PH.D. in biology and has a longstanding experience as Entrepreneur in a Start-Up developing human monoclonal antibodies for cancer treatment. Since being part of HTGF in 2015 Frank built a solid portfolio of start-ups with a focus on drug development companies. Out of this portfolio several companies entered the clinical stage, and 2 companies (Amal Therapeutics and Cardior Pharmaceuticals) were successfully exited to global pharma companies Boehringer Ingelheim with a deal volume of up to 1030 Mio. €.